Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimetoran in Cutaneous Lupus Erythematosus
NCT04493541Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) comparing Afimetoran with Placebo (2 arms). Primary endpoints: Incidence of Serious Adverse Events at 24 weeks, Incidence of Adverse Events at 20 weeks and 6 more. Started Aug 2020; status: completed.
02
Drugs
afimetoran
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT04493541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493541.